U.S. Markets closed
  • S&P 500

    4,538.43
    -38.67 (-0.84%)
     
  • Dow 30

    34,580.08
    -59.71 (-0.17%)
     
  • Nasdaq

    15,085.47
    -295.85 (-1.92%)
     
  • Russell 2000

    2,159.31
    -47.02 (-2.13%)
     
  • Crude Oil

    66.22
    -0.28 (-0.42%)
     
  • Gold

    1,782.10
    +21.40 (+1.22%)
     
  • Silver

    22.57
    +0.25 (+1.12%)
     
  • EUR/USD

    1.1317
    +0.0012 (+0.1019%)
     
  • 10-Yr Bond

    1.3430
    -0.1050 (-7.25%)
     
  • Vix

    30.67
    +2.72 (+9.73%)
     
  • GBP/USD

    1.3235
    -0.0067 (-0.5029%)
     
  • USD/JPY

    112.8000
    -0.4090 (-0.3613%)
     
  • BTC-USD

    49,190.17
    +1,485.75 (+3.11%)
     
  • CMC Crypto 200

    1,367.14
    -74.62 (-5.18%)
     
  • FTSE 100

    7,122.32
    -6.89 (-0.10%)
     
  • Nikkei 225

    28,029.57
    +276.20 (+1.00%)
     

Esperion (ESPR) Q2 Earnings Top, Drug Sales Hurt by Coronavirus

  • Oops!
    Something went wrong.
    Please try again later.
·5 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Esperion Therapeutics, Inc. ESPR recorded earnings per share of $4.32 per share in the second quarter of 2020, significantly higher than the Zacks Consensus Estimate of $2.13 per share. The company had incurred loss of $2.01 per share in the year-ago period.

The company generated revenues of $212.2 million, which were marginally less than the Zacks Consensus Estimate of $213.0 million. The company had recorded revenues of $1.0 million in the year-ago quarter.

Esperion’s stock has declined 38% so far this year compared with the industry’s 5% decrease.

 

 

Quarter in Details

In February, the FDA approved the company’s two drugs — Nexletol and Nexlizet — as a treatment for elevated LDL-C (bad cholesterol) in patients with hypercholesterolemia or mixed dyslipidemia. Please note that while Nexletol is bempedoic acid monotherapy tablet, Nexlizet is a combination of bempedoic acid and Merck’s MRK Zetia (ezetimibe).

The drugs were launched virtually amid the COVID-19 pandemic. While Nexletol was launched in March, Nexlizet was launched in June. COVID-19 led to lower new patient starts for both the drugs due to lower accessibility of patients and customer-facing team to doctors. However, the trends improved in July. The company said that prescription volume in July was 97% higher than June despite rising infection rates in the country.

Meanwhile, the company has achieved high-quality and broad managed care coverage with more than 80% commercial coverage and more than 50% Medicare Part D coverage for both drugs in the United States

Both these drugs received approval in Europe in April. In Europe, Nexletol will be available as Nilemdo and Nexlizet as Nustendi. Please note that the company has an agreement with Daiichi Sankyo to commercialize Nilemdo and Nustendi in Europe. Daiichi will initiate commercial rollout of the drugs in Europe in the fourth quarter.

Revenues in the reported quarter included $0.6 million of net product sales of Nexletol and $211.6 million in collaboration revenues. Product sales were hurt by COVID-19 (as discussed above) and more measured wholesaler inventory management and reordering patterns

The collaboration revenue was significantly higher in the quarter as it included $60 million of upfront payment from Japanese company Otsuka Pharmaceutical and $150.0 million of milestone payment from Daiichi Sankyo. In April, Esperion signed a development and commercialization deal for Nexletol and Nexlizet tablets in Japan with Otsuka.

Research and development (R&D) expenses decreased 18.2% from the year-ago period to $35.0 million. The decline was mainly driven by lower costs following the completion of enrollment in the ongoing cardiovascular outcomes study (CVOT) study on Nexletol. The study is evaluating the medicine’s impact on occurrence of major cardiovascular events in statin-intolerant patients with, or at high risk for, cardiovascular disease.

Selling, general and administrative expenses (SG&A) were $47.7 million, compared with $13.5 million in the year-ago period. The significant increase was primarily due to costs to support commercialization activities for Nexletol and Nexlizet.

As of Jun 30, 2020, Esperion had cash, cash equivalents and investment securities of $300.7 million compared with $158.2 million as of Mar 31, 2020.

2020 Guidance Updated

Esperion maintained its previously issued guidance for R&D and SG&A costs. The company anticipates R&D expense for 2020 to be in the range of $135-$145 million. SG&A expense guidance was also maintained in the range of $200-$210 million.

Zacks Rank & Stocks to Consider

Esperion currently carries a Zacks Rank #3 (Hold).

Esperion Therapeutics, Inc. Price, Consensus and EPS Surprise

 

Esperion Therapeutics, Inc. Price, Consensus and EPS Surprise
Esperion Therapeutics, Inc. Price, Consensus and EPS Surprise

Esperion Therapeutics, Inc. price-consensus-eps-surprise-chart | Esperion Therapeutics, Inc. Quote

Some better-ranked stocks from the biotech sector include Emergent Biosolutions EBS and Horizon Therapeutics HZNP, both sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Emergent Biosolutions’ earnings per share estimates have moved up from $3.45 to $5.60 for 2020 in the past 30 days. The company delivered an earnings surprise of 127.41%, on average, in the last four quarters. The stock has risen 141.3% so far this year.

Horizon Therapeutics’ earnings per share estimates have increased from $1.78 to $2.16 for 2020 in the past 30 days. The company delivered an earnings surprise of 38.63%, on average, in the last four quarters. The stock has surged 109.5% so far this year.

Zacks’ Single Best Pick to Double

From thousands of stocks, 5 Zacks experts each picked their favorite to gain +100% or more in months to come. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.

With users in 180 countries and soaring revenues, it’s set to thrive on remote working long after the pandemic ends. No wonder it recently offered a stunning $600 million stock buy-back plan.

The sky’s the limit for this emerging tech giant. And the earlier you get in, the greater your potential gain.

Click Here, See It Free >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Merck Co., Inc. (MRK) : Free Stock Analysis Report
 
Emergent Biosolutions Inc. (EBS) : Free Stock Analysis Report
 
Horizon Therapeutics Public Limited Company (HZNP) : Free Stock Analysis Report
 
Esperion Therapeutics, Inc. (ESPR) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research